openPR Logo
Press release

Global Pediatric HIV Infection Treatment Market: Emerging Economies Expected to Influence Growth until 2026 with Top Market players- GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, ViiV Healthcare, Camber Pharmaceuticals Inc., Johnson & Johnson Services

11-10-2018 08:21 AM CET | Health & Medicine

Press release from: Fact.MR

Global Pediatric HIV Infection Treatment Market: Emerging

During the past few years, the global burden of pediatric HIV infection is becoming a challenge for the healthcare industry. According to the World Health Organization, it is estimated that around 3.2 million people were living with HIV infection at the end of 2013. Majority of children acquire HIV infection from their HIV-infected mothers during pregnancy, breastfeeding or birth. Effective treatments can reduce the risk of mother-to-child HIV transmission. However, in most of the resource-limited countries where the burden of HIV is high, the treatment for pediatric HIV infection is still not widely available. Pediatric HIV infection causes immunologic deterioration, opportunistic infections, and cancers. Diagnosis of pediatric HIV infection includes viral antibodies and virologic nucleic acid amplification tests. Viral antibodies are given to children above 18 months whereas virologic nucleic acid amplification tests (such as PCR) are performed in children less than 18 months. Combination of antiretroviral drugs is given for the treatment of pediatric HIV infection. The general pathophysiology of pediatric HIV infection is similar to that in adults however, the clinical presentations, the method of infection and treatments often differ.  

Request 100 Page Sample Report Now: https://www.factmr.com/connectus/sample?flag=S&rep_id=874

The market for pediatric HIV infection treatment is primarily driven by increasing prevalence of HIV infection in children. Active involvement of national and international government bodies to promote the research on HIV infection treatment drugs is responsible to drive the growth of the market during the forecast period. Moreover, increasing private-public partnerships for the research and development activities and increasing healthcare expenditure are also some of the factors driving the growth of the Pediatric HIV Infection Treatment Market. However, unavailability of treatment options in the underdeveloped countries can be the factor which can hamper the growth of global pediatric HIV infection treatment market. Moreover, the limited number of treatment options with a very high cost of branded drugs in various regions have impeded the growth of the global pediatric HIV infection treatment market.

Worldwide, each year, about 150,000 more children are infected (7 to 10% of all new infections) with HIV infection, and about 110,000 children die. Some of the risk factors related to the vertical transmission of HIV infection in children include high plasma viral RNA concentrations, seroconversion during pregnancy or breastfeeding, advanced maternal disease, and low maternal peripheral CD4+ T-cell counts. The most common signs of pediatric HIV infection not receiving ART include generalized lymphadenopathy, splenomegaly, oral candidiasis, hepatomegaly, CNS disease, failure to thrive, recurrent bacteremia, lymphoid interstitial pneumonitis, hepatitis, nephropathy, and others.

Get Access To TOC Covering 200+ Topics: https://www.factmr.com/report/874/pediatric-hiv-infection-treatment-market

The global market for pediatric HIV infection treatment is segmented on basis of HIV infection types, treatment, distribution channel and geography:

Segmentation by Type
Not symptomatic
Mildly symptomatic
Moderately symptomatic
Severely symptomatic
Segmentation by Treatment
Antiretroviral (ARV) drugs
Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Protease Inhibitor (PI)
Integrase Strand Transfer Inhibitor (INSTI)
Others
Supportive care
Segmentation by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drugstore
e-commerce
On the basis of geography, global pediatric HIV infection treatment market is segmented into six key regions viz. North America, Latin America, Europe, Asia Pacific excluding China, China and Middle East & Africa. North America is expected to witness faster revenue growth in comparison with markets in other regions owing to higher infection rate amongst children and a large number of pediatric population suffering from HIV infection. Asia Pacific is also one of the fast growing regions in the global pediatric HIV infection treatment market due to high involvement of government-non-government bodies in promoting HIV infection treatment campaigns. Moreover, the Middle East and Africa and Latin America are expected to show less growth in the global pediatric HIV infection treatment market due to delayed introduction of treatment therapies in the regions.

Examples of some of the key players present in the global pediatric HIV infection treatment market are GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, ViiV Healthcare, Camber Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Apotex Inc., and others.

The report covers exhaustive analysis on:

Pediatric HIV Infection Treatment Market Segments
Pediatric HIV Infection Treatment Market Dynamics
Historical Actual Market Size, 2012 - 2016
Pediatric HIV Infection Treatment Market Size & Forecast 2016 to 2024
Pediatric HIV Infection Treatment Market Current Trends/Issues/Challenges
Competition & Companies involved
Pediatric HIV Infection Treatment Market Drivers and Restraints
Regional analysis includes

North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies of key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance
Ask Industry Expert about this Report: https://www.factmr.com/connectus/sample?flag=AE&rep_id=874

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Pediatric HIV Infection Treatment Market: Emerging Economies Expected to Influence Growth until 2026 with Top Market players- GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, ViiV Healthcare, Camber Pharmaceuticals Inc., Johnson & Johnson Services here

News-ID: 1359671 • Views:

More Releases from Fact.MR

Hemoglobinopathy Market Forecast Growing at 8.3% CAGR to Reach $1.7 Billion by 2034
04-24-2024 | Health & Medicine
Fact.MR
Hemoglobinopathy Market Forecast Growing at 8.3% CAGR to Reach $1.7 Billion by 2 …
In 2024, the global hemoglobinopathy market (ヘモグロビン症市場) is estimated to be worth US$788.1 million, with a projected compound annual growth rate (CAGR) of 8.3% through 2034. By 2034, the market size is expected to exceed US$1,745.7 million. The rise of genetic testing has led to a significant shift in the hemoglobinopathy market towards personalized medication. Companies are leveraging this trend to develop tailored treatment plans based on each patient's DNA
Sales Forecast of Elder Care Product Market to Reach US$ 56.7 Billion by 2034 with a 6.7% CAGR
04-24-2024 | Health & Medicine
Fact.MR
Sales Forecast of Elder Care Product Market to Reach US$ 56.7 Billion by 2034 wi …
The global elder care product market (高齢者介護製品市場) is anticipated to reach a value of US$ 29,600.2 million by 2024 and is expected to exceed US$ 56,719.4 million by 2034. Sales of these products are forecasted to grow at a CAGR of 6.7% through 2034, driven by the growing trend of aging-in-place. This trend is fueling innovations in technology integration, wearable health devices, and personalized safety solutions. Increasing awareness about elder
Veterinary Oncology Market Predicts 12% CAGR Through 2033 With a US$ 800 Million
04-24-2024 | Health & Medicine
Fact.MR
Veterinary Oncology Market Predicts 12% CAGR Through 2033 With a US$ 800 Million
In 2023, the veterinary oncology market (獣医腫瘍学市場) was valued at US$ 260 million, and it's anticipated to reach US$ 800 million by the end of 2033, with a projected compound annual growth rate (CAGR) of 12% from 2023 to 2033. Veterinary oncology focuses on caring for pets diagnosed with cancer, with the goal of enhancing their overall quality of life. Cancer is the leading cause of mortality among companion animals,
Sales of Luxury Eyewear are forecasted to reach US$ 56 billion by 2033
Sales of Luxury Eyewear are forecasted to reach US$ 56 billion by 2033
According to Fact.MR, a trusted provider of market research and competitive intelligence, the global Luxury Eyewear Market was valued at US$ 40 billion in 2023. Projections suggest that by the conclusion of 2033, this market is anticipated to escalate to US$ 56 billion. Forecasts indicate a steady Compound Annual Growth Rate (CAGR) of 3.4% in the global demand for luxury eyewear from 2023 to 2033. The surge in luxury eyewear sales

All 5 Releases


More Releases for HIV

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral